clinical trial · NCT06880549
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.·phase1·active not recruiting·n = 57
Advanced Solid TumorsmRNA-4106Nivolumab/Relatlimab
brief summary
The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.
started
Mar 25, 2025
primary completion
Jan 10, 2029
completion
Jan 10, 2029
last updated
Feb 5, 2026
official title
A Phase 1, Open-label, Multicenter, Dose-escalation Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol